Global Osteoporosis Drugs Market 2016:Bisphosphonates, Calcitonin

Osteoporosis is a condition in which the bones become weak and fragile due to the loss of tissue. This condition can arise due to hormonal changes, the deficiency of calcium or vitamin. In osteoporosis, the microstructure of bones is changed due to the change in bone mass and bone density. Osteoporosis can cause severe injury or pain and requires timely treatment. Osteoporosis patients find it difficult to comply with the strict dosage schedules of drugs, hence the drug developers are focusing on the production of osteoporosis drugs with easy dosage patterns. The increasing incidences of osteoporosis, a considerable rise in the geriatric populations along with a large prevalence of sedentary lifestyles, would supplement the developments and growth in the global osteoporosis drugs market over the analysis period. The use of RANK Ligand Inhibitors to treat osteoporosis has created opportunities for new as well as existing players, to develop new drugs in the market. Factors restraining the market growth are stringent regulatory environment and the time consuming drug approval process.

Access Full Report: http://www.intenseresearch.com/market-analysis/world-osteoporosis-drugs-market-opportunities-and-forecasts-2014.html

The global osteoporosis market, is segmented on the basis of Drug Type, Application and Geography. The drug types considered, in this report include Parathyroid Hormone Therapy (PTH) Drugs, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators (SERMs), RANKL (Receptor activator of nuclear factor kappa-B ligand) Inhibitors and Others (Vitamin D, Calcium). Based on applications the market is classified into Primary Type 1 Osteoporosis, Primary Type 2 Osteoporosis and Secondary Osteoporosis. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA. One of the strategies adopted by major market players is product launch. For instance, recently in 2015, Eli Lilly has launched a product named teriparatide, a new drug for osteoporosis. This drug, which can be self-injected is being delivered to patients houses directly without middlemen ship of pharmacies, which has helped company to earn additional margins. The companies profiled in this report are Aegis therapeutics, Amgen, Bone medical, Chugai pharmaceutical, Eli lilly, Merck & co., Novartis pharma, Novo nordisk, Ranbaxy laboratories and Osteologix.

Request a Brochure of This Report, here: http://bit.ly/2davZtI

About Intense Research

Intense Research provides a range of marketing and business research solutions designed for our client’s specific needs based on our expert resources. The business scopes of Intense Research cover more than 30 industries includsing energy, new materials, transportation, daily consumer goods, chemicals, etc. We provide our clients with one-stop solution for all the research requirements.

Contact Us:

Joel John
3422 SW 15 Street, Suit #8138,
Deerfield Beach, Florida 33442,
United States
Tel: +1-386-310-3803
GMT Tel: +49-322 210 92714
USA/Canada Toll Free No. 1-855-465-4651
Email: sales@intenseresearch.com
Web: http://www.intenseresearch.com/

This release was published on openPR.